drugset / Trial / NCT03103152
A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression
Phase 2/3
Completed
104 enrolled
Queen Mary University of London
Barts and the London School of Medicine and Dentistry · collabCancer Research UK · collab
RandomizedFactorialQuadruple-blindPrevention
Summary
To demonstrate the acceptability and feasibility of recruitment to a randomised chemoprevention study of standard (300mg) or low dose (100mg) aspirin vs. placebo and/or Vitamin D3 vs. placebo in patients enrolled on an Active Surveillance programme for prostate cancer.
Timeline
- Start
- 2016-12
- Primary completion
- 2020-03-31
- Completion
- 2020-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 100 mg | — |
| Subject | Aspirin | Small molecule | 300 mg | — |
| Subject | Vitamin D | Other / unclassified | 4000 iu | — |